ࡱ;   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry  \pCalc Ba=@  =@ 8X@"1Calibri1Arial1Arial1Arial1Calibri General3._(\$* #,##0_);_(\$* \(#,##0\);_(\$* \-_);_(@_) #,##0\(#,##0_);[RED]\(#,##0\)!"($"#,##0_);[RED]"($"#,##0\)'""($"#,##0.00_);[RED]"($"#,##0.00\) #,##0.00                + ) , *   (  (8  $  $  (  $  $  $ "8  $ (8 ` <condensed balance sheets"Pcondensed statements of op")fcondensed statements of st"9condensed statements of canet loss per share"_notes to condensed financi 4 property and equipment$notes to condensed financi-1$notes to condensed financi-2$anotes to condensed financi-3$notes to condensed financi-4$knotes to condensed financi-5$notes to condensed financi-6"comparison of the three mo"#research and development e$research and development e-1"1comparison of the six mont$Q research and development e-2$research and development e-3"wliquidity and capital resoS! exhibit index,exhibit index-1Btable of contentsQtable of contents-1=btable of contents-2"mgmedimmune limited phasebio$imedimmune limited phasebio-1$-lmedimmune limited phasebio-2"nas adopted pursuant to sec$wqas adopted pursuant to sec-1"Gtsection 906 of the sarbane$wsection 906 of the sarbane-1TRJ!       3  @@   qICONDENSED BALANCE SHEETSJune 30, 2021December 31, 2020AssetsCurrent assets:Cash and cash equivalentsReceivable from sublicense !Prepaid expenses and other assetsTotal current assetsProperty and equipment, net#Operating lease right-of-use assets Other assets Total assets%Liabilities and stockholders' deficitCurrent liabilities:!Current portion of long-term debt.Current portion of deferred sublicense revenueAccounts payable.Accrued expenses and other current liabilitiesTotal current liabilitiesLong-term debt, net Operating lease liabilities, net Deferred sublicense revenue, net Development derivative liabilityOther long-term liabilitiesTotal liabilities(Commitments and contingencies ( Note 9 )Stockholders deficit:Preferred stock, $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding at June 30, 2021 and December 31, 2020Common stock, $0.001 par value; 200,000,000 shares authorized; 48,057,720 shares issued and 48,027,753 shares outstanding at June 30, 2021; 29,471,854 shares issued and 29,441,887 shares outstanding at December 31, 2020PTreasury stock, at cost, 29,967 shares as of June 30, 2021 and December 31, 2020Additional paid-in capitalAccumulated deficitTotal stockholders deficit+Total liabilities and stockholders' deficit"CONDENSED STATEMENTS OF OPERATIONSThree Months Ended June 30,Six Months Ended June 30,20212020RevenueSublicense revenue$ Grant revenue Total revenueOperating expenses:Research and developmentGeneral and administrativeTotal operating expensesLoss from operationsOther income (expense):;Loss from remeasurement of development derivative liabilityInterest incomeInterest expenseForeign exchange gain (loss)Total other expenseNet loss before income taxesProvision for income taxesNet loss,Net loss per common share, basic and diluted=Weighted average common shares outstanding, basic and diluted5CONDENSED STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT) Common StockTreasury StockAdditional Paid-in CapitalAccumulated Deficit(Total Stockholders' Equity (Deficit)SharesAmountBalance at December 31, 20200Issuance of common stock in public offering, netExercises of stock optionsStock-based compensationBalance at March 31, 2021Stock offering costs=Issuance of common stock through employee share purchase planBalance at June 30, 2021Balance at December 31, 2019!Issuance of common stock warrantsExercise of stock optionsBalance at March 31, 2020Balance at June 30, 2020"CONDENSED STATEMENTS OF CASH FLOWSOperating activitiesKAdjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortizationNon-cash interest expense)Non-cash research and development expenseOther non-cash transactions,Changes in operating assets and liabilities:Other receivablesDeferred sublicense revenue%Net cash used in operating activitiesInvesting activities#Purchases of property and equipment+Acquisition of intellectual property rights%Net cash used in investing activitiesFinancing activities.Proceeds from development derivative liability>Proceeds from issuance of common stock in public offering, net)Payments of deferred stock offering costs'Proceeds from exercise of stock optionsRepayments of long-term debt)Net cash provided by financing activities4Net increase (decrease) in cash and cash equivalents8Cash and cash equivalents at the beginning of the period2Cash and cash equivalents at the end of the period%Supplemental disclosure for cash flowCash paid for interestFSupplemental disclosure of non-cash investing and financing activitiesIIssuance of warrants in conjunction with development derivative liabilityZInitial recognition of operating lease right-of-use assets and operating lease liabilitiesQPurchases of property and equipment by incurring development derivative liabilityUPurchases of property and equipment included in accounts payable and accrued expensesNet Loss Per ShareAs of June 30,Common stock options!Warrants to purchase common stockEmployee stock purchase planTotal'Notes to Condensed Financial Statements)Fair Value Measurements at Reporting DateLevel 1Level 2Level 3As of June 30, 2021:Cash equivalents Liabilities)Development derivative liability (Note 8)As of December 31, 2020:4. Property and EquipmentAs of June 30, 2021As of December 31, 2020 Lab equipment)Computer hardware, software and telephoneFurniture and fixturesLeasehold improvementsConstruction in progressLess accumulated depreciation"Accrued clinical and related costs&Accrued compensation and related costsAccrued interest,Current portion of operating lease liability Accrued otherTransaction Price(Cumulative Sublicense Revenue RecognizedDeferred Sublicense RevenueLicense#Development and Regulatory ServicesSupply of License Product=Less current portion of long-term deferred sublicense revenue+Total long-term deferred sublicense revenueYears Ending December 31,2021 (remaining six months)20222023 ThereafterTotal principal paymentsLess unamortized loan feesTotal term loan borrowings Development Derivative LiabilityFunding during the periodChange in fair valueYear Ending December 31,20242025#Total future minimum lease paymentsLess: Present value adjustmentOperating lease liabilitiesThree Months Ended June 30,Six Months Ended June 30,Total stock-based compensation;Comparison of the Three Months Ended June 30, 2021 and 2020ChangeForeign exchange gain Research and Development Expense$Preclinical and clinical development!Compensation and related benefitsFacilities expenseOther'Total research and development expenses5External research and development expense by program: Bentracimab Pemziviptadil-Unallocated research and development expense:)Compensation and stock-based compensationOther research and development9Comparison of the Six Months Ended June 30, 2021 and 2020Liquidity and Capital Resources EXHIBIT INDEXIncorporated by ReferenceExhibit Number Exhibit TitleFormFile No.Exhibit Filing DateSAmended and Restated Certificate of Incorporation of PhaseBio Pharmaceuticals, Inc.8-K 001-38697October 22, 2018=Amended and Restated Bylaws of PhaseBio Pharmaceuticals, Inc.S-1/A 333-227474October 5, 2018Form of Warrant to Purchase Shares of Series B Redeemable Convertible Preferred Stock, issued by PhaseBio Pharmaceuticals, Inc. on December 22, 2009.S-1September 21, 2018Warrant to Purchase Shares of Series C-1 Redeemable Convertible Preferred Stock, issued by PhaseBio Pharmaceuticals, Inc. to Silicon Valley Bank on October 18, 2017.Fourth Amended and Restated Investor Rights Agreement, by and among PhaseBio Pharmaceuticals, Inc. and certain of its stockholders, dated August 27, 2018.~Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to Silicon Valley Bank on March 25, 2019.10-KMarch 26, 2019Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to WestRiver Innovation Lending Fund VIII, L.P. on March 25, 2019.Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to WestRiver Innovation Lending Fund VIII, L.P. on July 26, 2019.10-QAugust 14, 2019}Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to Silicon Valley Bank on July 26, 2019.Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to Silicon Valley Bank on October 2, 2019.November 14, 2019Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to WestRiver Innovation Lending Fund VIII, L.P. on October 2, 2019.Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceu<nticals, Inc. to SFJ Pharmaceuticals X, Ltd. on January 9, 2020March 30, 2020:Description of PhaseBio Pharmaceuticals, Inc. Common Stock10.1# qLicense Agreement, dated as of June 16, 2021, by and between PhaseBio Pharmaceuticals, Inc. and Alfasigma, S.p.A.10.2# Acknowledgement of Grant of a Sublicense in Accordance with the License Agreement between Medimmune Limited and PhaseBio Pharmaceuticals, Inc. and Related OptionsTABLE OF CONTENTSARTICLE 1 DEFINITIONSARTICLE 2 GRANT OF RIGHTS2.1. Grants to Licensee2.2. Grants to MedImmune2.3. SublicensesG2.4. Retention of Rights; Limitations Applicable to License Grants&2.5. Licensed Product ExclusivityV2.6. Exceptions related to AstraZeneca Product Exclusivity Commitment of Licensor%2.6. Trademark License Agreement2.8. Upstream Agreements2.9. Territory RestrictionARTICLE 3 GOVERNANCE3.1. Alliance Managers"3.2. Joint Steering Committee$3.3. Discontinuation of the JSC4.1. Manufacturing4.2. Development4.3. Regulatory Activities4.4. Commercialization74.5. Statements and Compliance with Applicable Law4.6. Markings4.7. Subcontracting(4.8. Product Positioning Principles#ARTICLE 5 PAYMENTS AND RECORDS5.1. Upfront Payment5.2. Milestones5.3. Royalties&5.4. Royalty Payments and Reports"5.5. Mode of Payment; Offsets5.6. Taxes#5.7. Interest on Late Payments5.8. Financial Records5.9. Audit5.10. Audit Dispute$ARTICLE 6 INTELLECTUAL PROPERTY,6.1. Ownership of Intellectual Property06.2. Maintenance and Prosecution of Patents 6.3. Enforcement of Patents.6.4. Infringement Claims by Third Parties<6.5. Invalidity or Unenforceability Defenses or Actions6.6. Product TrademarksE6.7. Corporate Names, Licensed Trademarks and Product Trademarks1ARTICLE 7 CONFIDENTIALITY AND NON-DISCLOSURE%7.1. Confidentiality Obligations7.2. Permitted Disclosures7.3. Use of Name7.4. Public Announcements7.5. Publications7.6. Securities Laws,7.7. Return of Confidential Information-ARTICLE 8 REPRESENTATIONS AND WARRANTIES/8.1. Mutual Representations and Warranties@8.2. Additional Representations and Warranties of MedImmune"8.3. DISCLAIMER OF WARRANTIES58.4. Anti-Bribery and Anti-Corruption ComplianceARTICLE 9 INDEMNITY&9.1. Indemnification of MedImmune%9.2. Indemnification of Licensee$9.3. Indemnification Procedures,9.4. Special, Indirect and Other Losses9.5. Insurance$ARTICLE 10 TERM AND TERMINATION10.1. Term and Expiration10.2. Termination10.3. Rights in Bankruptcy&10.4. Consequences of Termination10.6. Remedies010.7. Accrued Rights; Surviving ObligationsARTICLE 11 MISCELLANEOUS11.1. Force Majeure11.2. Export Control11.3. AssignmentF11.4. Certain Transactions Involving MedImmune and its Affiliates11.5. Severability11.6. Dispute Resolution211.7. Governing Law, Jurisdiction and Service11.8. Notices'11.9. Entire Agreement; Amendments11.10. English Language11.11. Equitable Relief011.12. Waiver and Non-Exclusion of Remedies'11.13. No Benefit to Third Parties11.14. Further Assurance'11.15. Relationship of the Parties11.16. References11.17. Construction11.18. Counterparts3MEDIMMUNE LIMITED PHASEBIO PHARMACEUTICALS, INC.ALFASIGMA S.P.A.eBy: /s/ Pier Vincenzo Colli Name: Pier Vincenzo Colli Title: Chief Executive Officer4Signed: Name: Title: Date:DAS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002August 12, 2021By:/s/ Jonathan P. Mow)Jonathan P. Mow Chief Executive Officer/s/ John P. Sharp'John P. Sharp Chief Financial Officer-SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 !j<Bcc   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} % , @ , , , , , , , , , , , , , , , , , , , , , , , , , , ,           ~ " ~  j   ~       ~ 2X  ~    ~ f  ~ Vs   ~ .  ~    ~   ~    ~   ~    ~ v$ ~       ~ "T ~  S   ~ B      ~ :. ~  j9   ~ "d ~  \   ~  ~     ~ ? ~  i   ~ j ~  2   ~       ~ s ~  (   ~   ~     ~ P ~              ~  ~  v  ,! ," ,# ,$ ,  ~   ~   ! !~ !f)! !~ ! _!  "! "~ "" "~ " 6"  #" #~ #f# #~ # :v#  $# $~ $v$$ $~ $ $ *                                         !!!!!!!! """""""" ######## $$$$$$$$ PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} ,,,,,, , , , , ,,,,,,,,,,,,, $  % & '  (  ' (  )4 * ~    +   ~   + ,          ~  - ~      ~   ~   .4  / ~   ~ E  ~ Z  ~   0 ~ >  ~ 2  ~ r  ~ d  1 ~ ~  ~ x  ~ :{  ~ \  2 ~  ~  z   ~ R& ~ : 34 4 ~  ~     ~ v ~  5 ~  ~  V   ~  ~  6 ~   ~     ~  ~ . 7   ~  Z   ~  ~ j 8 ~ ڡ ~     ~  ~ . 9 ~ X ~  JH   ~ n ~ f_ : ~       ~    ; ~ ? ~  JH   ~ n ~ f_ < 433333 ~  {   ~  ~  = ~ >p  ~  !   ~ bu  ~ "(b                                                                     PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} '*,* @*,),),), ), ), ), ), ),),),),),*,),),),),),),),), >  ? @ A !B"& 'C ()  D E D E) F ~  ~  v   ~ + ~  ~ _  ~ !6" $&~ ':v( G ~  c ~  N       ~   !" $&~ 'Ҫ( H ~            ~ f  !" $&~ 'f( I             ~ z    ! " $&~ 'z  ( ;                 ~ !T " $&~ 'T ( J ~ –p   ~   ~ +  ~   ~ R   ~ !j " $&~ 'n ( K             ~ v   ! " $&~ 'v ( H ~ ~8           ~    ! " $&~ ' ( L ~ f          ~ *  !" $&~ '*( I            ~ b   !" $&~ 'b ( ;               ~ !?" $&~ '?( M ~ 5u  ~     ~ + ~  ~ f)  ~ !" $&~ 'f(Z) N ~ N ~  v   ~ + ~  ~ Ύ   ~ !J" $&~ '*( O            ~ {  !" $&~ '{( P ~ r          ~ F  !" $&~ 'F( I            ~ ^  !" $&~ '^( ;               ~ !" $&~ '( Q ~ u ~  v   ~ + ~  ~ B  ~ !f1" $&~ 'C( G ~ .          ~ f  !" $&~ 'f( H ~ R          ~   !" $&~ '( ),!),&), I             ~    ! " $&~ ' ( !; ! !! ! ! !  !  !! ! !! ! !! ! ~ !!JH!" !$&~ !'JH!( &R &~ &:f& &~ & v&  & ~ &+& &~ && &~ &"& & ~ &!y&" &$&~ &'f&(2 f   !#$&') !#$&')   !"$&'(   !"$&'(   !"$&'(           !" $& '(           !" $& '(           !" $& '(           !" $& '(           !" $& '(   !"$&'(   !"$&'(   !"$&'(   !"$&'(   !#$&')   !"$&'(   !"$&'(   !"$&'(   !"$&'(   !"$&'(   !"$&'(   !"$&'(   !"$&'(           !" $& '(!!!!!!!! !! !!!!!!!!!!!! !!!"!!$&!!'(&&&&&&&& && &&&&&&&&&&&& &&!"&&$&&&'(PH0 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} - , , , , , , , , , , , , , , , , , , , , , , , , , , , , , S  & '  (   T ; ~ n ~  f_  U V ~   ~   I ~   ~ Z  4 ~ p  ~  A  W ~   ~   X ~ fr  ~ Y  Y   ~    Z  ~      [   ~  F   ~ ^ ~     ~  ~  :C   ~ > ~    \ ~      ] ~ Z ~    ^ _ ~  ~  &  `   ~  r  a ~  ~    b c   ~    d ~  ~  b  e ~ b ~  F  f ~ ~ ~  J  ,! ," ,# ,$ ,% ,& ,' ,( ,) ,* ,+ ,, , L ~ *     !g !~ !f! ! ! !  "h "~ "f" "~ " "  #i #~ #7# #~ # #  $j $~ $j$ $~ $ $  %k %~ %"% %~ % <%  &l& 'm '~ '' '~ ' '  (n( )o ) )+) )~ ) {)  *p * *+* *~ * *  +q +~ +A+ + + ++  ,r ,~ ,, ,~ , *,                                          !!!!!!!! """""""" ######## $$$$$$$$ %%%%%%%% &&&&&&&& '''''''' (((((((( )))))))) ******** ++++++++ ,,,,,,,, PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , , , , , , , s  t '  (   u ~   ~  >R  v ~ nh ~  nh  w ~  ~    x ~ F  ~ :E         PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} ,,,,,, , , , , ,,, y  x  z"    {  | }  ~4 4  ~  ~      +  + 4   ~ s   +   +  ~ s  4  4   ~   ~    +   +  4  ~ (   +    + ~ ([                                                PH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , @ , , , , , , , ,         ~ R ~     ~ 2 ~  2   ~  ~     ~ 6 ~     ~ j  ~ J  ~   ~    ~ J  ~    ~ .  ~  *%                 PHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , @ , , , , , , y        ~ F= ~  +   ~ . ~  R#   ~  ~     ~ r ~  .   ~ r  ~    ~ "d  ~ \            PH 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  ,,,,,, , , y         ~  ~      +  ~ ^) ~     ~ '  ~ jo      ~ jo ~ 8 ~     ~  " ~   " ~  Z+                    PH$0(  $>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  ,,,,,, , , , y   ~ *  ~ >U  ~ N     ~ &   ~    ~ Ɠ       PH(0(  (>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  ,,,,,, y    F ~ (  ~   ~ p M ~ sZ PH,0(  ,>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} ,,,,,, , , , , , y   ~ n  ~   ~   ~ ^  ~ n   ~ ^   ~    ~    ~            PH00(  0>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , @,,,, y    '  (  ' (  0 ~  ~  J   ~ b ~   / ~ n ~     ~ z ~   ~ f  ~     ~  ~ Z"$          PH40(  4>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} ,,,,,, , , , , ,,,,,,,,,,   %   '  (  )( * ~    +   ~  - ~       ~  .(  / ~   ~ E  ~ e  0 ~ >  ~ 2  ~ >   1 ~ ~  ~ x  ~ q  2 ~   ~ z  ~ /  3( 4 ~  ~     ~  5 ~  ~  V   ~  6 ~   ~     ~     ~  Z   ~  8 ~ ڡ ~     ~   9 ~ X ~  JH   ~  : ~       ~  ; ~ ? ~  JH   ~ zo                                                     PH80(  8>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  ,,,,,, , , ,   %   '  (   ~ >x ~  n!   ~ V  ~  ~     ~  I ~ n ~     ~   ~ >  ~   ~ n   ~    ~   ~     ~   ~ E  ~ e j-                         PH<0(  <>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  ,,,,,,, , ,  %   '  (  (  ~ P ~     ~ B  ~ " ~  Q   ~  (  ~ :  ~     ~   ~   ~    ~     ~   ~ E  ~ e 2                        PH@0(  @>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} ,,,,,, , , , , ,,,,,,,,,,,   &    '  (  )( * ~    +   ~  ,   ~   ~  - ~   ~   ~   .(  / ~ Z  ~   ~   0 ~ r  ~ d  ~   1 ~ :{  ~ \  ~ r  2 ~ R& ~  :   ~ ~ 3( 4 ~ v ~     ~ ~ 5 ~  ~     ~ ~ 6 ~  ~  .   ~ j 7 ~  ~  j   ~  8 ~  ~  .   ~  9 ~ n ~  f_   ~  N : ~       ~  ; ~ n ~  f_   ~  5v                                                      PHD0(  D>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  ,,,,,, , , ,   &   '  (   ~  ~  ְ   ~   ~ 29 ~  4   ~ n I ~ z ~     ~   ~    ~   ~     ~   ~ z  ~    ~ Z  ~   ~  j-                         PH H0(  H>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  ,,,,,,, , ,  &    '  (  (  ~ X ~  7   ~ !  ~ E ~  l   ~  (  ~ ? ~  9   ~ &  ~ +  ~   ~    ~ Z  ~   ~  3                       PH0L0(  L>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , , , , , , ,   & '  (   ] ~ Z ~    a ~  ~    h ~ f ~    i ~ 7  ~          PH@P0(  P>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} !,!,!,!,!,!, !, !, !, !, !,   .           ~      ~    H ~      ~ S   H   ffffff@       ~     H  ~        ~     H  Ji                                                                PHPT0(  T>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} !!,!,!,!,!,!,!, !, !, !, !, !,!,!,!,!,!,!,!,!,!,!,~      @   H @     @   H ~       ~     H ffffff@     ffffff@   H  ~ [       ~ [    H  ~        ~     H  @     @   H ffffff@     ffffff@   H q= ףp@     q= ףp@   H  : H  : H                                                                                                      PH`X0(  X>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} ),,,,,, , , , , ,,,,,,,,,,,,,,,,,,,   ~    ~ V   ~ V   ~ V   ~ V   ~ Z   ~ ^   ~ b   ~ b   ~ b   ~ f   ~ j   ~ j   ~ j   ~ ~   ~ ~   ~    ~    ~    ~    ~    ~    ~    ~    ~    ~    ~    ~   ,!,",#,$,%,&,',(,  ~   ! !~ ! ! " "~ " " # #~ # # $ $~ $ $ % %~ % % & &~ & & '  '~ ' ' (  (~ ( (ZK            !!!!""""####$$$$%%%%&&&&''''((((PHp\0(  \>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} +,,,,,,, , , , , ,,,,,,,,,,,,,,,,,,,   ~     ~     ~     ~    ~    ~    ~    ~    ~ &   ~ &   ~ .   ~ 2   ~ 2   ~ 2   ~ 2   ~ 6   ~ >   ~ B   ~ B   ~ B   ~ B    ~ F  ! ~ N  " ~ N  # ~ N  $ ~ N  % ~ N  & ~ f  ' ~ f  ( ~ ~  ,!,",#,$,%,&,',(,),*, ) ~ ~  !* !~ ! ! "+ "~ " " #, #~ # # $- $~ $ $ %. %~ % % &. &~ & & '/ '~ ' ' (0 (~ ( ( )1 )~ ) ) *2 *~ * *R            !!!!""""####$$$$%%%%&&&&''''(((())))****PH`0(  `>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  ,,,,,,, , , , 3 ~   4 ~   5 ~   6 ~   7 ~   8 ~   9 ~   : ~   ; ~   < ~        PHd0(  d>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} ,, @ = >   ?  PHh0(  h>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , , @ = >  @  *  PHl0(  l>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , , @ = >  @  *  PHp0(  p>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , , @ A B  C  D     E  J   PHt0(  t>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , , @ A B  C  F     G  J   PHx0(  x>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , , @ H B  C  D     E  J   PH|0(  |>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , , @ H B  C  F     G  J   PH0(  >@<dgg   FMicrosoft Excel 97-TabelleBiff8Oh+'0|8 @ L X d p0@@@k@k՜.+,D՜.+,\ H AppVersion DocSecurityHyperlinksChangedLinksUpToDate ScaleCrop ShareDoc12.0000 Root EntryFWorkbookyCompObjIOle SummaryInformation(DocumentSummaryInformation8h